Jazz Pharmaceuticals (JAZZ) stock surged 5.05% in Wednesday's intraday trading session, fueled by the company's impressive Q4 2024 earnings report and optimistic analyst commentary.
On Sunday, Jazz Pharmaceuticals announced its Q4 2024 financial results, which included record-breaking revenue of nearly $1.1 billion, a 15% year-over-year increase in net product sales for its blockbuster drug Epidiolex, and strong performances across its oncology portfolio. The company also provided upbeat revenue and earnings guidance for 2025, projecting continued growth.
Following the earnings release, multiple Wall Street analysts reaffirmed their bullish stance on JAZZ, with some raising their price targets on the stock. Baird analyst Joel Beatty raised his price target to $167, citing the company's strong execution and promising growth prospects. Stifel Nicolaus and Bank of America Securities also reiterated their "Buy" ratings on JAZZ.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.